PharmaResearch Expands Global Reach Through European Partnership
In a significant move aimed at enhancing its international presence, PharmaResearch, a leader in regenerative medicine, has announced a strategic partnership with VIVACY, a prominent French medical aesthetics company. This collaboration will pave the way for the distribution of the innovative medical device brand, Rejuran, across Europe, covering 22 countries, including critical markets like the UK, Germany, and France.
Strategic Goals of the Partnership
The agreement between PharmaResearch and VIVACY is not merely a business transaction but a strategic alliance that leverages VIVACY's extensive distribution network and market expertise. This partnership aims to capitalize on VIVACY's existing relationships and distribution capabilities to enhance the entry of Rejuran into the European market. By doing so, PharmaResearch is optimistic about establishing a robust foothold in a competitive landscape.
Investment and Market Reach
This partnership involves a commitment valued at approximately EUR 54.5 million over a five-year period, and it encompasses key Western European nations. This substantial investment underscores the importance both companies place on succeeding in this market.
Launch Strategy for Rejuran
With plans to initiate distribution soon, PharmaResearch aims to follow a phased rollout across Europe. The anticipated distribution timeline suggests that the key European locations will receive Rejuran within the short term, setting the stage for rapid brand recognition and market capture.
Leadership Remarks
Jihoon Sohn, the CEO of PharmaResearch, expressed confidence in their product, stating, "Rejuran is currently the only Polynucleotide-based medical device approved under the EU Medical Device Regulation (MDR). We believe this partnership will not only boost its visibility but also reinforce its status as a leading skin booster in the international medical aesthetics sector." His forward-looking comment highlights the brand’s potential to redefine skincare solutions globally.
VIVACY's Perspective
Bertrand, the CEO of VIVACY, also shared his views, claiming that the premium positioning of Rejuran, coupled with VIVACY's scientific credibility and commercial prowess, creates an ideal environment for a successful market introduction. He indicated that their alliance represents a commitment to providing pioneering solutions in skin regeneration to physicians and patients alike.
About PharmaResearch
PharmaResearch stands out as a biopharmaceutical innovator dedicated to enhancing human health through advanced regenerative solutions. With a diverse portfolio including medicines, medical devices, and cosmetics, the company is focused on utilizing unique ingredients like DOT™ PDRN and DOT™ PN, which are protected by multiple patents. The company's headquarters located in Gangwon-do, South Korea, serves as the base for its development initiatives, while it also maintains a presence in Costa Mesa, California.
About Laboratoires VIVACY
As a pioneer in the field of regenerative aesthetics, Laboratoires VIVACY has been at the forefront of manufacturing premium hyaluronic acid-based medical devices since its inception in 2007. Based in Paris, the company is acclaimed for its innovative IPN-Like Technology and is recognized globally for its STYLAGE® dermal fillers and DESIRIAL®, which is notable for its application in functional and aesthetic gynecology. With operations extending across more than 85 countries, VIVACY emphasizes advancing medical aesthetics through research and development.
Frequently Asked Questions
What is the purpose of the PharmaResearch and VIVACY partnership?
The partnership aims to distribute Rejuran across Europe, leveraging VIVACY's established network to enhance market penetration and brand visibility.
How much is the investment in this partnership?
The partnership agreement is valued at approximately EUR 54.5 million over five years.
When will Rejuran be available in Europe?
PharmaResearch plans to start distributing Rejuran in key European markets within the current year, followed by a phased rollout.
What distinguishes Rejuran in the market?
Rejuran is the only Polynucleotide-based medical device approved under the EU Medical Device Regulation, enhancing its competitive edge in the aesthetic market.
What technology does VIVACY utilize in its products?
VIVACY utilizes innovative IPN-Like Technology in its medical devices, which is acclaimed for its effectiveness in aesthetic treatments.
